Cesar Santa-Maria, MD
Medical Oncology · Baltimore, MDNPI 1134381692
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Athenex Pharmaceutical Division, LLC at 42.6% of the total. Reporting peaked in 2020 at $3,650 and has fallen 96.3% since, to $134 in 2025.
Across 27 payments — averaging $306.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Athenex Pharmaceutical Division, LLC$4K
- Seagen Inc.$1K
- E.r. Squibb & Sons, L.L.C.$937
- Halozyme Inc$900
- AstraZeneca$807
- Eli Lilly$800
- plus $148 from 2 others
Across 95 payments — averaging $41,979 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.3M
- Hoffmann-la Roche Limited$250K
- Tesaro, Inc.$191K
- Astrazeneca UK Limited$158K
- AstraZeneca$49K
- Novartis$42K
- plus $39K from 1 others
What the payments were for
- Consulting fees$2,85034%
- Speaking & faculty fees$3,99648%
- Travel & lodging$7689%
- Food & beverage$6388%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Athenex Pharmaceutical Division, LLC | 8 | $3,522 |
| Seagen Inc. | 1 | $1,150 |
| E.r. Squibb & Sons, L.L.C. | 8 | $937 |
| Halozyme Inc | 1 | $900 |
| AstraZeneca | 5 | $807 |
| Eli Lilly | 1 | $800 |
| Gilead | 2 | $137 |
| Genentech, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oral Paclitaxel$3,500
- Encequidar$3,500
- TUKYSA$1,150
- Trodelvy$125
How this compares
$8,264 in reported general payments places this provider in the 55th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 16 | $226,157 |
| Anastrozole | 65 | $1,567 |
| Exemestane | 11 | $1,353 |
| Letrozole | 14 | $585 |
| Oxycodone Hcl | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.